The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8). Materials and Methods PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data. Conclusion This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-10-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.12587PMID 27738317PMCID 5346692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adenosquamous carcinoma of the lung

  2018cited by this paper
• Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

  2016cited by this paper
• World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.

  2016cited by this paper
• Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features

  2015cited by this paper
• Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

  2015cited by this paper
• EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

  2015cited by this paper
• A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

  2014cited by this paper
• Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung

  2014cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients

  2014cited by this paper
• EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis.

  2014cited by this paper
• Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cance

  2014cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma

  2013cited by this paper
• EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy

  2013cited by this paper
• Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung

  2013cited by this paper
• Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

  2013cited by this paper
• Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

  2013cited by this paper
• KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

  2013cited by this paper
• EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence.

  2013cited by this paper
• Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma

  2013cited by this paper
• Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.

  2013cited by this paper
• Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

  2013cited by this paper
• EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

  2013cited by this paper
• Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

  2013cited by this paper
• Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients

  2013cited by this paper
• Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer

  2013cited by this paper
• Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers

  2013cited by this paper
• Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

  2012cited by this paper
• Impact of age on epidermal growth factor receptor mutation in lung cancer.

  2012cited by this paper
• Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

  2012cited by this paper
• Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer

  2012cited by this paper
• National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China.

  2012cited by this paper
• Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

  2012cited by this paper
• Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasound‐guided transbronchial needle aspiration

  2012cited by this paper
• Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

  2012cited by this paper
• Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

  2012cited by this paper
• Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.

  2012cited by this paper
• Detection of epidermal growth factor receptor mutations in small specimens of non-small cell lung cancer by amplification refractory mutation system

  2012cited by this paper
• EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma

  2012cited by this paper
• Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer

  2012cited by this paper
• Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.

  2012cited by this paper
• Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

  2012cited by this paper
• Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort

  2012cited by this paper
• EGFR mutations in non‐small‐cell lung cancer among smokers and non‐smokers: A meta‐analysis

  2012cited by this paper
• A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

  2012cited by this paper
• Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

  2012cited by this paper
• Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.

  2012cited by this paper
• EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma

  2012cited by this paper
• Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients

  2012cited by this paper
• EGFR Somatic Mutations in Lung Tumors: Radon Exposure and Passive Smoking in Former- and Never-Smoking U.S. Women

  2012cited by this paper
• EGFR mutations as a predictive marker of cytotoxic chemotherapy.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

  2012cited by this paper
• Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.

  2012cited by this paper
• Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer

  2012cited by this paper
• High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features

  2012cited by this paper
• First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

  2012cited by this paper
• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

  2012cited by this paper
• Routine EGFR and KRAS Mutation analysis using COLD‐PCR in non‐small cell lung cancer

  2012cited by this paper
• Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.

  2012cited by this paper
• Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

  2011cited by this paper
• Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

  2011cited by this paper
• Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

  2011cited by this paper
• Pre- and post-chemotherapy mutation status of epidermal growth factor receptor gene in non-small cell lung cancer

  2011cited by this paper
• Disparities in outcomes in Hispanic patients with non-small cell lung cancer (NSCLC): Evaluation of differences of predictive biomarker expression.

  2011cited by this paper
• Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients

  2011cited by this paper
• Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America

  2011cited by this paper
• [High-resolution melting analysis for the detection of EGFR mutations in circulating DNA of lung cancer patients].

  2011cited by this paper
• Genetic and epigenetic changes in lung carcinoma and their clinical implications

  2011cited by this paper
• [Epidermal growth factor receptor gene mutations, amplification and clinicopathologic correlation in patients with lung cancer].

  2011cited by this paper
• Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer

  2011cited by this paper
• Epidermal Growth Factor Receptor Mutations Are Associated with Docetaxel Sensitivity in Lung Cancer

  2011cited by this paper
• ALK rearrangement in a selected population of advanced non-small cell lung cancer patients: FISH and inmunohistochemistry diagnostic methods, prevalence, and clinical outcomes.

  2011cited by this paper
• Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

  2011cited by this paper
• 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

  2011cited by this paper
• Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations

  2011cited by this paper
• Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer.

  2011cited by this paper
• Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing

  2011cited by this paper
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

  2011cited by this paper
• Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma

  2011cited by this paper
• Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations.

  2011cited by this paper
• Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

  2011cited by this paper
• Use of CT-guided fine needle aspiration biopsy in epidermal growth factor receptor mutation analysis in patients with advanced lung cancer

  2011cited by this paper
• [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].

  2011cited by this paper
• Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma

  2011cited by this paper
• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  2011cited by this paper
• Screening for EGFR mutations in lung cancer, a report from India.

  2011cited by this paper
• Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer

  2011cited by this paper
• Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

  2011cited by this paper
• Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.

  2011cited by this paper
• The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases

  2011cited by this paper
• Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

  2011cited by this paper
• Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

  2011cited by this paper
• Detection of Epithelial Growth Factor Receptor Mutations in Cerebrospinal Fluid from Patients with Lung Adenocarcinoma Suspected of Neoplastic Meningitis

  2011cited by this paper
• [Detection of epidermal growth factor receptor gene mutations and its clinical significance in non-small cell lung cancers].

  2011cited by this paper
• Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.

  2011cited by this paper

• Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.

  2026cites this paper
• Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.

  2026cites this paper
• Ginkgetin inhibits non-small cell lung cancer via the HSP90-AKT signaling pathway.

  2026cites this paper
• Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.

  2026cites this paper
• First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

  2026cites this paper
• EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study

  2026cites this paper
• Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.

  2026cites this paper
• Functional significance of miR-218 in lung cancer

  2026cites this paper
• Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

  2026cites this paper
• Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

  2026cites this paper
• Domain-derived knowledge enabled machine learning and functional characterization of cancer-associated RNA methylation sites.

  2026cites this paper
• Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study

  2026cites this paper
• Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.

  2026cites this paper
• Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.

  2026cites this paper
• Geographic disparities and health inequality evolution in the disease burden of tracheal, bronchus, and lung cancer in Asia: a 33-year longitudinal analysis and future projections

  2026influential citation
• Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.

  2026cites this paper
• Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.

  2026cites this paper
• Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.

  2026cites this paper
• Structure-based identification of natural EGFR modulators from Codariocalyx motorius using computational approaches

  2026cites this paper
• Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions

  2026cites this paper
• Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies

  2026cites this paper
• Ultra-Rapid EGFR Testing in Non-Small Cell Lung Carcinoma Patients: Findings from a Canadian Clinical Testing Workflow.

  2025cites this paper
• Identifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks

  2025cites this paper
• Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer

  2025cites this paper
• Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China

  2025cites this paper
• Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto

  2025cites this paper
• Geographical Inequalities and Comorbidities in the Timely Diagnosis of NSCLC: A Real-Life Retrospective Study from a Tertiary Hospital in Western Greece

  2025cites this paper
• Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy

  2025cites this paper
• Prognostic Outcomes of Spinal Metastasis: Timing of Metastasis Presentation Matters.

  2025cites this paper
• Tuberculosis Coinciding With Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Diagnostic Conundrum

  2025cites this paper
• Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach

  2025cites this paper
• Mitigation and management of adverse events associated with amivantamab therapy

  2025cites this paper
• microRNA-196b-5p expression in cancer tissues is closely associated with clinical and pathological characteristics and prognosis of patients with non-small cell lung cancer

  2025cites this paper
• The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing.

  2025cites this paper
• Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study

  2025cites this paper
• Differences in Safety Signal Detection Between Osimertinib and First- and Second-Generation EGFR-TKIs: A Pharmacovigilance Study Using a Spontaneous Reporting System.

  2025cites this paper
• Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States

  2025cites this paper
• An evaluation of patritumab deruxtecan for the treatment of EGFR-mutated non-small cell lung cancer

  2025cites this paper
• Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors

  2025cites this paper
• Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

  2025cites this paper
• Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies

  2025cites this paper
• Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated AEs.

  2025cites this paper
• Molecular Profiling in Non-Small-Cell Lung Cancer: A Single-Center Study on Prevalence and Prognosis

  2025cites this paper
• Companion Diagnostic FDA Review Flexibilities: An Assessment of CDx for NSCLC to Support Aligned Approaches for Validation

  2025cites this paper
• Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I–III NSCLC

  2025cites this paper
• Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib

  2025cites this paper
• ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

  2025cites this paper
• Radiation therapy for cerebral metastases: Non-stereotactic treatment options.

  2025cites this paper
• Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

  2025cites this paper
• Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report

  2025cites this paper
• Temporal Trends and Patient Stratification in Lung Cancer: A Comprehensive Clustering Analysis from Timis County, Romania

  2025influential citation
• Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

  2025cites this paper
• In silico exploration of anticancer plant phytochemicals for EGFR-targeted lung cancer therapy

  2025cites this paper
• Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study

  2025cites this paper
• The Current Consensus on Salvage Surgery after Targeted Therapy for Advanced EGFR-Mutant Non-Small Cell Lung Cancer

  2025cites this paper
• Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.

  2025cites this paper
• A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).

  2025cites this paper
• Direct Ser797 Interacted Pteridine-7(8H)-one Derivatives as Highly Selective and Orally Available EGFRL858R/T790M/C797S Inhibitors.

  2025cites this paper
• Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.

  2025cites this paper
• Development of Ellagic- Acid Based Silver Doped Titanium Dioxide Nanoparticles Against Human A549 Cell Lines and Study of Their Mechanism at the Cellular Level

  2025cites this paper
• Enhancing Large-Scale Pharmacogenetic Studies in African Populations for Clinical Care and Drug Development.

  2025cites this paper
• RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC

  2025cites this paper
• Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)

  2025cites this paper
• [Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression].

  2025cites this paper
• Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.

  2025cites this paper
• The Impact of Leptomeningeal Metastasis in Patients with Non-Small Cell Lung Cancer with EGFR Mutation: Survival Analysis of a Retrospective Cohort Study

  2025cites this paper
• Recent Advances and Challenges in Cancer Care, with a Focus on Multiple Myeloma, Lymphoma, and Lung Cancer: Key Insights from the Onco Summit 2024-The APAC Chapter

  2025cites this paper
• Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses

  2025cites this paper
• Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma

  2025cites this paper
• The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients.

  2025cites this paper
• Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives

  2025cites this paper
• Identification of novel inhibitors for epidermal growth factor receptor tyrosine kinase using absolute binding free-energy simulations.

  2025cites this paper
• Epidermal Growth Factor Mutation Analysis in Patients With Bronchogenic Adenocarcinoma: Prevalence and Clinical Profile-Outlook From a Tertiary Care Center in India

  2025influential citation
• Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer

  2025cites this paper
• Epidermal Growth Factor Receptor Aberrations Identified by Next-Generation Sequencing in Patients with Metastatic Cancers

  2025cites this paper
• A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR‐Mutant Non‐Small Cell Lung Cancer

  2025cites this paper
• Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapy

  2025cites this paper
• Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

  2025cites this paper
• Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.

  2025cites this paper
• Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.

  2025cites this paper
• A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.

  2025cites this paper
• Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC

  2025cites this paper
• Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study.

  2025cites this paper
• Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study

  2025cites this paper
• Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma.

  2025cites this paper
• Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials

  2025cites this paper
• The curse of blood–brain barrier and blood–tumor barrier in malignant brain tumor treatment

  2025influential citation
• Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?

  2025cites this paper
• Health-promoting functions and related comprehensive molecular mechanisms of tea: from the perspectives of anti-inflammatory, lipid-lowering, glucose-lowering and anti-cancer effects

  2025cites this paper
• Immunohistochemical profile and molecular markers of lung carcinoma in tertiary care medical center - A retrospective observational study

  2025cites this paper
• A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

  2025cites this paper
• Retrospective database study of druggable mutation detection among patients with non-small cell lung cancer in Japan

  2025cites this paper
• Extracellular vesicle-associated epidermal growth factor receptor as a potential liquid biopsy biomarker in lung adenocarcinoma: a case-control study

  2025cites this paper
• Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells

  2025cites this paper
• Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement

  2025cites this paper
• STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models

  2025cites this paper
• Surgical and Perioperative Advances for Patients With Locally Advanced Non-Small Cell Lung Cancer.

  2025cites this paper
• Molecular Diagnosis, Clinical Trial Representation, and Precision Medicine in Minority Patients with Oncogene-Driven Lung Cancer

  2025cites this paper
• Rare sequential EGFR and ALK mutations in non-small cell lung cancer: A case report and literature review.

  2025cites this paper
• Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs

  2025cites this paper